Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other

Aurora Cannabis launches Daily Special in Germany

By The Northwire Desk — AI Analysis Dec 18, 2025 · 15:02 ACB · 7.71 Aurora Cannabis Inc
ACB · Price

Executive Summary

  • Aurora Cannabis Inc. has launched "Daily Special," a new medical cannabis brand specifically for the German market, aiming to provide high-quality, affordable flower to patients.
  • The launch is positioned as a strategic move to strengthen Aurora's presence in Germany, one of the world's most important medical cannabis markets, following the company's record performance.
  • The product is available at German pharmacies and via telemedicine platforms starting December 19, 2025.

Key Details

  • Product Name: Daily Special (Sativa-dominant cultivar).
  • Genetics: Born from Gelonade Biscotti.
  • Cannabinoid Profile: 21% to 23% THC; less than 1% CBD.
  • Flavor/Aroma Profile: Intense citrus, sweet-earthy, and diesel-forward aromas with a rich terpene profile.
  • Quality Standards: Produced under global Good Manufacturing Practice (GMP) standards.
  • Availability: German pharmacies and Telemedicine platforms.
  • Launch Date: December 19, 2025.
  • Strategic Context: Part of Aurora's effort to expand patient choice and affordability in the rapidly growing German medical cannabis sector.

Notable Quotes

  • "The launch of Daily Special in Germany is a clear demonstration of Aurora's long-term investment and leadership in one of the world's most important medical cannabis markets and key region for the company," said Andreas Dotterweich, senior vice-president, Aurora Europe.
Read the original news release →

More from Aurora Cannabis Inc

Jun 11, 2026 · 07:05

Record FY2026 revenue masks structural margin contraction and explicit FY2027 guide-cut; cash-rich but capital allocation remains dilutive.

Earnings May 14, 2026 · 08:45

Aurora Cannabis Secures IP Rights Amidst Sector Consolidation and Price Stabilization

M&A / Property May 14, 2026 · 06:54

Aurora Secures IP Moat Amidst Dilution Concerns and Cash Burn

M&A / Property Apr 28, 2026 · 15:57

Aurora Cannabis Expands Global Medical Portfolio Amidst Dilution Concerns and Profitability Push

Production / Operations Apr 28, 2026 · 06:53

Product Expansion Validates EU Capacity Play, But Dilution Risk Looms Over Cash Burn

Production / Operations Apr 15, 2026 · 07:05

Aurora Cannabis Acquires EU GMP Capacity Amidst Stock Decline

M&A / Property